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The United States Department of Agriculture’s Animal and Plant Health Inspection Service 
(APHIS) has regulated genetically engineered (GE) organisms since 987 and, in 00, 
established Biotechnology regulatory Services (BrS) to place a renewed emphasis and 
priority on biotechnology. APHIS has authorized more than 0,000 permits and notifica-
tions for the introduction of GE organisms and deregulated over sixty products for use, 
establishing itself as an international leader in the safe regulation of GE products. 
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APHIS	has	authorized	more	than	10,000	permits	and	
	notifications	for	the	introduction	of	GE	organisms	and	
	deregulated	over	sixty	products	for	use.	
As the science of biotechnology and the landscape in which it operates continue to 
evolve, APHIS’s role in regulating it becomes increasingly challenging. As a regulatory au-
thority of this rapidly growing technology, we must ensure that we protect US agriculture, 
allow for the safe development of GE organisms, and not unduly inhibit the advancement 
of the technology. One important challenge is to keep up with the science’s technological 
advances. An increasingly broad array of traits is being engineered into plants as scientists 
discover more genes from a wider assortment of organisms that might be useful to improve 
agriculture, protect the environment or benefit consumers. But perhaps one of the most 
challenging technological trends of the past few years, from a regulatory perspective, has 
been the use of agricultural crops to produce pharmaceutical compounds and other items 
not intended for food or feed. One regulatory challenge is to allow the cultivation of 
these and have effective systems in place that will prevent them from being mixed with 
other crops, some of which are to be used as food or feed. In addition, pharmaceutical 
technology has prompted interest from a new range of stakeholders. Since 987, BrS 
has issued 0 pharmaceutical and industrial permits in eleven crops; however, less than 
350 acres have been grown since 00. 
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Another important challenge is the changing social and political landscape. US citizens 
are becoming increasingly interested in biotechnology and want to play a larger role in 
government decision-making. In addition, citizens can be skeptical of the government 
and are willing to take action against government decisions. We have also seen an increase 
in the activity of public-interest groups who want to represent constituent views of the 
science and how government should regulate it. One outcome of this is that government 
agencies have become the target of lawsuits. In addition, biotechnology does not enjoy 
the same level of acceptance internationally as in the United States, posing an even greater 
challenge beyond our borders.
Biotechnology regulatory Services
Since its inception just 3 years ago, BrS has undergone significant reorganization and is 
better prepared to anticipate and respond to the challenges being brought forth by the 
evolving nature of biotechnology and the landscape. The newly reorganized BrS goes 
well beyond a staff of scientists to evaluate permit applications and petitions for deregula-
tion. It includes a Compliance and Inspection Branch, a Communications and Capacity 
Building Branch, a regulatory Analysis Branch, an Office of Science, and a forecasting 
function that help BrS address these challenges and keep pace with the advancing sci-
ence. In addition, we have developed five priority areas of emphasis that set program 
direction and provide the foundation for decision-making. These priority areas are the 
key to BrS’s ability to meet the challenges of regulating biotechnology in general, and 
specifically, plants engineered to produce pharmaceuticals.
The first priority is maintaining rigorous regulation that thoroughly and appropriately 
evaluates and ensures safety and is supported by strong compliance and enforcement. 
APHIS regulation relies on a science-based evaluation of risk, which will be even more 
important in the future. This approach allows us to focus our regulatory efforts on specific 
areas such as pharmaceutical plants and reduce burdens in areas of lower risk. In 003, we 
strengthened permit conditions for pharmaceuticals and industrials resulting in stringent 
confinement measures and a greater government role. For example, our confinement 
measures now include increased isolation distances and fallow zones, and restrict the use 
of the same land to produce pharmaceutical and industrial crops from the production 
of food or feed crops. APHIS also requires developers of pharmaceutical and industrial 
crops to have dedicated equipment and storage facilities for those crops. We currently 
inspect every pharmaceutical and industrial site at least seven times before, during, and 
after production. In addition, in 003, APHIS amended its regulations to require that 
industrials are tested under the permit system.
The	first	priority	is	maintaining	rigorous	regulation	that	
thoroughly	and	appropriately	evaluates	and	ensures	safety	and	is	
supported	by	strong	compliance	and	enforcement.	
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Environmental Impact Statement
to ensure that our regulations remain effective as the technology advances, APHIS is 
currently preparing an Environmental Impact Statement (EIS) that will be used in revis-
ing its regulations. The updated regulations will leverage the additional authorities of the 
Plant Protection Act of 000, significantly broadening APHIS’s authority and positioning 
the USDA to address a broader range of issues, including human health. In the Notice 
of Intent that was published in January 00, we stated that we are considering numer-
ous revisions. One change we are considering is the implementation of a multi-tiered, 
risk- and familiarity-based permitting system to replace the current permitting and no-
tification system. With respect to pharmaceuticals, another change we are considering is 
a new mechanism for maintaining regulatory oversight after a crop is commercialized. 
This mechanism would feature increased transparency and efficiency, and a greater role 
for the states. We are also considering the establishment of safety criteria that might allow 
for the deregulation of certain pharmaceutical crops. 
reducing the regulatory Burden
BrS is also committed to reducing the regulatory burden as appropriate to the risk. We 
appreciate that this is especially important for publicly funded researchers and small busi-
nesses. In pursuing this goal, we requested feedback on ways we could reduce regulatory 
burden in our January 00 Federal register notice that announced our intent to prepare 
an environmental impact statement on our proposed regulation changes. In addition, we 
have held workshops with the Pew Initiative on Food and Biotechnology and with USDA’s 
Agricultural research Service and Cooperative State research, Education, and Extension 
Service to identify possible regulatory barriers and potential solutions. The Ir- program 
for pesticide registration for use on minor crops has been proposed as a model that the 
government might follow to reduce the burden imposed on researchers and small busi-
nesses who are developing GE crops. It has also been suggested that alliances might be 
established between small businesses and university researchers such that the burden on 
generating required data might be shared, and thereby not be prohibitive to any individual 
researcher or small company who might seek to develop a GE crop. 
Fostering the technology
In addition to maintaining rigorous regulation, it is critical that we administer a compli-
ance program that is strong enough to ensure the safety of the science while also allowing 
for the advancement of the technology. This is especially true for higher risk crops, such 
as those used to produce pharmaceuticals. BrS’s Compliance and Inspection Branch is 
dedicated exclusively to ensuring that researchers maintain compliance through defined 
procedures that include violation-prevention efforts, risk-based criteria for quality inspec-
BRS	is	also	committed	to	reducing	the	regulatory	burden	as	
appropriate	to	the	risk.
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tion, standardized inspection and auditing processes, uniform enforcement, and thorough 
documentation of any compliance infractions. We also make investigation results available 
for public and stakeholder viewing. Compliance specialists and APHIS inspectors perform 
targeted inspections and audits of field tests and use established criteria to thoroughly 
evaluate all potential compliance infractions. 
The second priority is ensuring that our regulatory process and decision-making are 
transparent to stakeholders and the public. Being transparent about our processes, deci-
sions, and activities is critical for building public confidence in the regulatory system. 
We also understand that it is particularly important to be transparent in regard to phar-
maceuticals. We must meet the challenge of fulfilling this objective while also protecting 
developers’ confidential business information. Part of our transparency efforts include 
following the National Environmental Policy Act (NEPA), which establishes the crite-
ria on when to conduct an environmental assessment (EA). We make available on our 
Web-site all EAs conducted for pharmaceutical and industrial field tests, or in cases that 
we do not conduct an EA, we post APHIS’s categorical exclusion criteria and all NEPA 
decision documents. We also announce the EAs in the Federal register and allow for 
a comment period. Our Web-site also provides a listing of all pharmaceutical permits 
along with their current status, accompanying decision documents, total acreage, and 
any supplemental permit conditions. Though confidential business information (CBI) 
limits our ability to post all permit applications, we post as much information as we can. 
In one recent case, we posted permit applications where little or no CBI was claimed and 
in another recent case, we summarize the non-CBI information from permit applications 
in our EAs. In addition, even when specific location and size information of field tests 
is claimed as CBI, we provide the general location and size information. We have also 
completely redesigned our Web-site and have included a stakeholder registry that allows 
registered stakeholders to receive updates and other information relevant to selected topics 
of interest, such as regulation activities, communication and outreach, capacity building, 
and compliance issues.
In another effort to ensure transparency, in 00, we held multiple public meetings 
to discuss issues associated with the BrS proposal to revise regulations. BrS met with 
twenty-two stakeholder groups and heard a wide range of viewpoints on the proposed 
revisions and provided clarification on some of our agency’s objectives. In the near future, 
we will be holding similar stakeholder meetings on a monthly basis as we complete the 
process of developing a Programmatic EIS on our proposed regulatory changes.
Assuring Safety
The third priority is maintaining a science-based system that ensures that the best sci-
ence is used to support regulatory decision-making and to assure safety. While we work 
The	second	priority	is	ensuring	that	our	regulatory	process	and	
decision-making	are	transparent	to	stakeholders	and	the	public.
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to achieve this priority, we face the challenge of obtaining all of the available scientific 
information needed in order to make sound science-based decisions. to help achieve this 
goal, we have expanded our staff to include a diversified collection of scientific expertise 
in science fields, such as plant pathology, botany, entomology, ecology, animal science, 
virology, environmental science, biochemistry and molecular biology. to keep pace with 
this ever-evolving technology, BrS staff and scientists attend and host meetings and 
workshops, read literature, and interact with outside scientists, stakeholders, and the 
public. Additionally, in 00, BrS established the Office of Science, which works with 
the research community to identify biosafety research priorities and to communicate 
biosafety research results for the use of regulators globally. As part of its agenda, the Of-
fice of Science addresses scientific issues associated with pharmaceuticals and in August 
00, conducted a workshop on confinement that focused largely on pharmaceutical 
crops; more than 00 scientists and experts from six countries participated. The Office 
of Science also helps maintain science as the centerpiece of regulatory decision-making 
amidst the challenges of diverse political, economic, and personal viewpoints associated 
with the technology. We also encourage biotechnology research and are looking into the 
possibility of becoming a funding agency in the future, such that we might target areas 
of research that we identify as having a pressing need. 
The	third	priority	is	maintaining	a	science-based	system	that	
ensures	that	the	best	science	is	used	to	support	regulatory	decision-
making	and	to	assure	safety.
Communicating with Stakeholders
The fourth priority is maintaining communication, coordination, and collaboration 
with the full range of stakeholders. BrS works to meet the challenge of recognizing and 
reaching out to a broad range of stakeholders and interests. In regard to pharmaceuticals, 
it is particularly important to reach out to a broad diversity of stakeholders that includes 
not only the biotechnology industry and researchers, but also stakeholders such as in the 
food industry, commodity groups, public interest groups and the states. For example, 
we recently met with a food-industry group to discuss additional science-based measures 
that BrS should consider for two pharmaceutical field tests. 
In another example, we work closely with the states on issuing permits, particularly for 
pharmaceuticals. We provide information to support their decision-making, which may 
involve adding additional permit conditions to address the state’s concerns or, in some 
cases, providing support such that the state has a full understanding of the science.
The	fourth	priority	is	maintaining	communication,	coordination,	
and	collaboration	with	the	full	range	of	stakeholders.
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International Leadership
Finally, the fifth priority set forth by BrS is establishing international leadership to ensure 
that international biotechnology standards are science-based, international regulatory 
capacity-building is supported, and international implications of domestic policy and 
regulatory decisions are considered. BrS faces the challenge of providing international 
leadership to ensure the development of science- and risk-based regulatory systems while 
maintaining effective working relationships in which we recognize and respect the differ-
ences in their systems and they are in turn receptive to our approach and the benefits that 
it can offer. In addition, we must consider the international implications of any domestic 
policy decisions that we make and ensure that the policies that we put in place domesti-
cally can be applied equally internationally. These important international partnerships 
are now serving as a starting point for international discussions of the regulation and 
confinement of pharmaceutical crops.
Through our evolving regulatory structure, dedicated compliance function, focus 
on science and risk, increased transparency and communication with a broad range of 
stakeholders, we are focused on these priorities and managing the challenges posed by 
new trends such as pharmaceutical crops. As the science progresses, we will continue to 
evaluate the implications of new technologies, enhance our processes and procedures, 
and develop appropriate regulations to meet the challenges posed by this new science 
while continuing to safeguard American agriculture, the nation’s food supply and the 
environment.
The	fifth	priority	is	establishing	international	leadership.
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